Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Operating Income (2021 - 2026)

bioAffinity Technologies has reported Operating Income over the past 5 years, most recently at -$3.6 million for Q1 2026.

  • Quarterly Operating Income fell 37.68% to -$3.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$11.6 million through Mar 2026, down 20.0% year-over-year, with the annual reading at -$10.6 million for FY2025, 18.08% down from the prior year.
  • Operating Income was -$3.6 million for Q1 2026 at bioAffinity Technologies, down from -$3.1 million in the prior quarter.
  • Over five years, Operating Income peaked at -$684119.0 in Q2 2022 and troughed at -$3.6 million in Q1 2026.
  • The 5-year median for Operating Income is -$2.1 million (2024), against an average of -$2.1 million.
  • Year-over-year, Operating Income plummeted 159.95% in 2023 and then grew 13.97% in 2024.
  • A 5-year view of Operating Income shows it stood at -$1.6 million in 2022, then plummeted by 44.26% to -$2.3 million in 2023, then dropped by 25.79% to -$2.9 million in 2024, then decreased by 6.46% to -$3.1 million in 2025, then decreased by 15.3% to -$3.6 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Operating Income are -$3.6 million (Q1 2026), -$3.1 million (Q4 2025), and -$2.3 million (Q3 2025).